Gail J. Roboz, MD, Weill Cornell Medical Center

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 27th 2021

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Promising Data for Pevonedistat in High-Risk MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 27th 2021

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Emerging Role of Venetoclax in the Treatment of MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 27th 2021

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.

Treatment in Older Patients with High-Risk MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 20th 2021

Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.

Role of Transplant in MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 20th 2021

The panel of experts comment on the role of transplant in patients with myelodysplastic syndrome.

HMAs in High-Risk MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 13th 2021

The panel of experts comment on the optimal timing of hypomethylating agents and transplant in patients with high-risk myelodysplastic syndrome.

Use of HMAs for the Treatment of MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 13th 2021

The panel of experts highlight the risk factors and considerations for use of hypomethylating agents in patients with myelodysplastic syndrome versus acute myeloid leukemia.

Treatment of Transfusion Dependent MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 6th 2021

The panel of experts reflect on the use of lenalidomide in patients with myelodysplastic syndrome who are transfusion dependent.

Luspatercept: An Erythroid Maturation Agent in MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

August 6th 2021

Rami Komrokji, MD discusses the recent approval and FDA indication for the use of the erythroid maturation agent luspatercept.

ESA Use in the Treatment of MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 30th 2021

The panel of experts discusses considerations necessary when recommending treatment with erythropoiesis-stimulating agents in patients with myelodysplastic syndrome.

Guidelines for the Treatment of MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 30th 2021

Rami Komrokji, MD, discusses his approach to treatment in patients with myelodysplastic syndrome, while being mindful of recommended guidelines.

Individualized Treatment for MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 23rd 2021

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Staging Models in Diagnosis and Risk Assessment of MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 23rd 2021

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

The Impact of Mutational Status on Treatment Considerations for MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 16th 2021

James Foran, MD; Azra Raza, MD; and Gail Roboz, MD, discuss how mutation status in myelodysplastic syndrome may impact treatment considerations.

Clinical Considerations in the Diagnosis of Patients with MDS

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 9th 2021

Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center & Research Institute, discusses the importance of examining a patient’s complete blood count, nutritional status and bone marrow when considering a diagnosis of myelodysplastic syndrome.

Myelodysplastic Syndrome Diagnosis and Risk Assessment

Gail J. Roboz, MD, Weill Cornell Medical Center;Amy DeZern, MD, MHS;James M. Foran, MD;Rami Komrokji, MD;Azra Raza, MD, Columbia University Medical Center

July 9th 2021

Gail Roboz, MD; Azra Raza, MD; and Amy DeZern, MD, MHS, discuss the clinical considerations and risk assessments inherent to a diagnosis of myelodysplastic syndrome.